Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT07484074 is registered in ClinicalTrials.gov with Ollin Biosciences, Inc. as lead sponsor.

NCT NCT07484074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07484074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Lead sponsor
Ollin Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 12, 2025
Completion date
December 9, 2025
Enrollment
164 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme), neovascular (wet) age-related macular degeneration